Allarity Therapeutics announces DRP licensing and lab services deal with EU biotech

Allarity Therapeutics, Inc.

Non-exclusive global license to selected DRP algorithms in breast cancer granted to an undisclosed EU-based biotech company.
Allarity will provide advanced transcriptome analysis services from its Denmark lab; purchase commitments secured for next year.
Company states the agreement is not expected to have a significant impact on its financial outlook.
CEO Thomas Jensen says deal validates DRP platform and offsets internal operating costs.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.